PDF
File
Kurs
+23,29%
Likviditet
0,26 MSEK
Kalender
| Est. tid* | ||
| 2026-02-27 | 21:50 | Bokslutskommuniké 2025 |
| 2025-11-21 | 21:50 | Kvartalsrapport 2025-Q3 |
| 2025-08-22 | 21:50 | Kvartalsrapport 2025-Q2 |
| 2025-05-12 | N/A | X-dag ordinarie utdelning ATANA 0.00 SEK |
| 2025-05-09 | N/A | Årsstämma |
| 2025-05-09 | 21:50 | Kvartalsrapport 2025-Q1 |
| 2025-02-28 | - | Bokslutskommuniké 2024 |
| 2024-11-01 | - | Kvartalsrapport 2024-Q3 |
| 2024-10-31 | - | Extra Bolagsstämma 2025 |
| 2024-08-23 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-03 | - | Årsstämma |
| 2024-05-03 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-23 | - | Bokslutskommuniké 2023 |
| 2023-10-27 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-18 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-08 | - | X-dag ordinarie utdelning ATANA 0.00 SEK |
| 2023-05-05 | - | Årsstämma |
| 2023-05-05 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-24 | - | Bokslutskommuniké 2022 |
| 2022-12-07 | - | Extra Bolagsstämma 2022 |
| 2022-11-25 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-19 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-09 | - | X-dag ordinarie utdelning ATANA 0.00 SEK |
| 2022-05-06 | - | Årsstämma |
| 2022-05-06 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-25 | - | Bokslutskommuniké 2021 |
| 2021-11-26 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-17 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-10 | - | X-dag ordinarie utdelning ATANA 0.00 SEK |
| 2021-05-07 | - | Årsstämma |
| 2021-05-07 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-25 | - | Bokslutskommuniké 2020 |
| 2020-11-27 | - | Kvartalsrapport 2020-Q3 |
| 2020-11-09 | - | Extra Bolagsstämma 2020 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-11 | - | X-dag ordinarie utdelning ATANA 0.00 SEK |
| 2020-05-08 | - | Årsstämma |
| 2020-05-08 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-24 | - | Bokslutskommuniké 2019 |
| 2019-11-29 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-09 | - | Extra Bolagsstämma 2019 |
| 2019-08-07 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-08 | - | X-dag ordinarie utdelning ATANA 0.00 SEK |
| 2019-05-07 | - | Kvartalsrapport 2019-Q1 |
| 2019-04-05 | - | Årsstämma |
| 2019-02-26 | - | Bokslutskommuniké 2018 |
| 2018-05-08 | - | X-dag ordinarie utdelning ATANA 0.00 SEK |
| 2018-05-07 | - | Årsstämma |
| 2018-02-22 | - | Bokslutskommuniké 2017 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Nordic SME Sweden |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
The company's strategy to strengthen its position and establish strong relationships with five reference customers in the USA has now resulted in one of the country's leading health institutes ordering an upgrade from their Attana Cell™ 200 to Attana Cell™ 250. The order will impact Q1 results and Q2 cashflow.
The purpose of the upgrade is to streamline ongoing research projects. The primary goal for the customer is to enhance palliative care for cancer patients by donating T-cells from healthy individuals to the patients. The Company's technology is utilized to study interactions between human and animal T-cells with cancer cells and cancer tissue, expediting the transition from animal experiments to clinical trials. Ultimately, it can be used for personalized donation, thereby increasing the number of potential donors for a given patient.
I am very satisfied that our US-strategy is yielding results both financially and scientifically. The order is further evidence that our technology generates unique and valuable biological data. We look forward to continuing collaboration with the customer and strengthening our position in US, says Marcus Söderberg, CEO of Attana
Marcus Söderberg, CEO Attana AB
e-mail: ir@attana.com
tel: +46 708 86 23 00
This is information that Attana AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at the time stated by the Company's news distributor, Cision, at the publication of this press release.